Clinical trials
Phase 3 trials in Georgia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
409 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 12 |
| 2011 | 7 |
| 2012 | 8 |
| 2013 | 12 |
| 2014 | 21 |
| 2015 | 20 |
| 2016 | 20 |
| 2017 | 21 |
| 2018 | 27 |
| 2019 | 27 |
| 2020 | 29 |
| 2021 | 47 |
| 2022 | 27 |
| 2023 | 27 |
| 2024 | 43 |
| 2025 | 27 |
| 2026 | 20 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 230 |
| Active, not recruiting | 59 |
| Recruiting | 55 |
| Terminated | 51 |
| Unknown status | 7 |
| Enrolling by invitation | 6 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| argenx | 19 |
| Sanofi | 13 |
| Boehringer Ingelheim | 12 |
| UCB Biopharma SRL | 9 |
| Alvotech Swiss AG | 8 |
| Celgene | 8 |
| Teva Branded Pharmaceutical Products R&D, Inc. | 8 |
| Amgen | 7 |
| Hoffmann-La Roche | 7 |
| Regeneron Pharmaceuticals | 7 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 20 |
| Myasthenia Gravis | 16 |
| Breast Neoplasms | 15 |
| Colitis, Ulcerative | 15 |
| Multiple Sclerosis | 13 |
| Crohn Disease | 11 |
| Autoimmune Diseases | 9 |
| Multiple Sclerosis, Relapsing-Remitting | 9 |
| Neoplasm Metastasis | 9 |
| Epilepsy | 8 |
Trials
Showing 1 to 25 of 409. Each trial links to its page on Pharma Observatory.
309 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.